AMPHAmphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc. (AMPH) sells generic and branded prescription drugs, with a focus on respiratory and endocrine therapies. The next catalyst is Nov 5, 2026 — Q3 2026 Earnings Release and Guidance Reset, which will test the company’s ability to stabilize margins and deliver revenue growth amid rising costs and slowing branded product performance.
- Revenue fell 1.7% YoY to $721.33M in Q2 2026, with net income of $60.54M and diluted EPS of $0.67.
- Free cash flow (TTM) reached $265.45M, but net margin contracted to 8.4%, reflecting margin pressure.
- Debt-to-equity ratio of 0.11x suggests limited leverage, though growth is constrained by branded product slowdown.
The Read
Amphastar's stock dropped sharply twice in early 2026, first on a significant Q4 earnings miss and weak guidance highlighting margin pressure from rising costs and slowing branded product growth, then further on disappointing revenue outlook and margin concerns despite FDA approval of a new drug.
The schedule
No upcoming catalysts on the current packet.
Past
- Wed23Sep
The earnings release will test whether the company can deliver stronger-than-expected revenue and margin guidance, which could shift the narrative from the previous quarter's mixed results. The focus will be on the guidance reset and its implications for future cash flow and product mix.
- Thu6Aug
Actual outcome: Bull · $21.60 at outcome
Amphastar Pharmaceuticals (AMPH) reported Q2 2026 earnings in line with estimates, with GAAP net income of $0.67 per share and adjusted non-GAAP net income of $0.91 per share. The company highlighted revenue growth driven by recently launched products, including ipratropium bromide inhalation, and mentioned ongoing efforts to address an FDA warning letter at its IMS subsidiary. These developments, combined with management's focus on pipeline and U.S. manufacturing investments, supported the stock's rally toward the bull target.
Following a severe margin contraction in Q1, the Q2 print will be scrutinized for operating leverage and BAQSIMI stabilization. Reaffirming 2026 guidance and showing sequential margin improvement could lift shares from a $16.50 base to $19.00.
- Thu7May
Actual outcome: Bear · $19.39 at outcome
Amphastar reported Q1 2026 adjusted earnings of $0.42 per share, significantly missing consensus estimates of $0.70, alongside net revenues of $171.2 million. The substantial earnings miss, combined with management noting rebate and discounting pressures on its BAQSIMI product, drove a sharp sell-off that sent the stock down 19.3% over the following month.
- Thu26Feb
Actual outcome: Bear · $19.83 at outcome
Amphastar significantly missed Q4 earnings estimates ($0.73 vs. $0.97 expected) and issued weak FY26 revenue guidance that signaled a deceleration in key branded products like Primatene MIST and Glucagon. The stock plummeted as rising R&D and SG&A costs pressured margins, leading analysts to label the company a 'value trap' and downgrade price targets due to the lack of net income stabilization.